Fair Value Calculator Fair Value Calculator
EN DE

FAMILYCARE (FAMILYCARE) Fair Value & Analysis

IN · Market cap ₹156M

F FAMILYCARE FAMILYCARE · BSE
Price₹2.88
Fair Value₹4.26
Upside+48.0%
Quality37/100
Watch FAMILYCARE for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range ₹3.19 – ₹5.34

Fair value as of: Jul 5, 2026

From 6 valuation models · updated today

Share price −10.8% over the past month.

Price vs Fair Value (12 months)

₹5.62 ₹2.62 Fair Value ₹4.26 Jun 2025 Jul 2026

12‑month range ₹2.62 – ₹5.62 · fair‑value band ₹3.19 – ₹5.34 · the ₹2.88 price screens below the ₹4.26 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

FAMILYCARE (FAMILYCARE) currently trades at ₹2.88, while our model-based Fair Value estimate is ₹4.26 — implying the stock looks roughly 48.0% undervalued today. We read business quality at 37/100 (below-average quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Trailing-twelve-month revenue stands at ₹2.1M. Revenue grew 141.2% year over year. It earns a return on equity of -75.8%. Net debt stands at ₹31.6M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹3.19 (bear case) to ₹5.34 (bull case); at ₹2.88, the current price sits below that range. The share trades about 51% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹2.1M
Revenue growth (YoY) +141%
Return on equity -75.8%
Free cash flow −₹176M FY2025
Operating margin -4,567%
EPS (TTM) ₹-0.9700
More key figures
EPS growth (YoY) -88.7%
Net debt ₹31.6M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

FAMILYCARE reported revenue of ₹79.0M in FY2025 versus ₹354M in FY2021, a compound −31.2%/yr. Reported net income was −₹441M in FY2025.

Revenue −31.2%/yr
FY21 ₹354M
FY22 ₹421M
FY23 ₹420M
FY24 ₹400M
FY25 ₹79.0M
Net income
FY21 ₹40.7M
FY22 ₹52.0M
FY23 ₹52.6M
FY24 ₹125M
FY25 −₹441M

Is FAMILYCARE fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "FAMILYCARE Fair Value". https://www.fairvalue-calculator.com/stock/FAMILYCARE

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is FAMILYCARE (FAMILYCARE) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹4.26 versus a price of ₹2.88 — about +48% (undervalued). Model-based estimate, not financial advice.
What is the fair value of FAMILYCARE?
Our model-based fair value for FAMILYCARE is ₹4.26 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹2.88.
What is the quality score of FAMILYCARE?
FAMILYCARE has a Quality Score of 37/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of FAMILYCARE (FAMILYCARE)?
FAMILYCARE reported trailing-twelve-month revenue of about ₹2.1M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of FAMILYCARE?
The net profit margin of FAMILYCARE is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.